Cryoablation plus sintilimab and lenvatinib in advanced or metastatic intrahepatic cholangiocarcinoma: a phase 2 trial
8.0
来源：
Nature
关键字：
CRISPR
发布时间：
2025-11-02 07:33
摘要：
The CASTLE-01 trial evaluated the efficacy of cryoablation combined with sintilimab and lenvatinib in patients with advanced intrahepatic cholangiocarcinoma (ICC). The study found a 75% objective response rate, with median progression-free survival of 16.8 months and overall survival of 25.4 months. The combination therapy was well tolerated and showed potential to enhance systemic antitumor immunity, suggesting a new treatment paradigm for ICC. These findings highlight the importance of innovative approaches in addressing the rising incidence of ICC globally.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+1.0分
business_impact
1.0分+1.0分
scientific_rigor
1.5分+1.5分
timeliness_innovation
1.5分+1.5分
investment_perspective
2.5分+2.5分
market_value_relevance
1.0分+1.0分
team_institution_background
0.5分+0.5分
technical_barrier_competition
1.0分+1.0分
关键证据
The objective response rate assessed was 75.0%, meeting the prespecified primary endpoint.
Cryoablation combined with sintilimab and lenvatinib represents a promising approach for treatment.
The trial demonstrated significant clinical efficacy with median progression-free survival of 16.8 months.
真实性检查
否
AI评分总结
The CASTLE-01 trial evaluated the efficacy of cryoablation combined with sintilimab and lenvatinib in patients with advanced intrahepatic cholangiocarcinoma (ICC). The study found a 75% objective response rate, with median progression-free survival of 16.8 months and overall survival of 25.4 months. The combination therapy was well tolerated and showed potential to enhance systemic antitumor immunity, suggesting a new treatment paradigm for ICC. These findings highlight the importance of innovative approaches in addressing the rising incidence of ICC globally.